These findings suggest a DNA methylation-driven ARID1A-PI3K/AKT/mTOR -PD-L1 cascade as a potential immune evasion pathway, providing preclinical rationale for exploring epigenetic modulation to enhance immunotherapy efficacy in GC. The gene discussed is MTOR; the disease is gastric cancer.